[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569885":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":35,"collaborators":7,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Institut Bergonié","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Nadège ANIZAN","STUDY_DIRECTOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+33556333347","n.anizan@bordeaux.unicancer.fr",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Institut Bergonie","RECRUITING","Bordeaux","33600","France",{"type":25,"coordinates":26},"Point",[27,28],-0.58046,44.84124,{"lat":28,"lon":27},[31,32],{"name":10,"role":14,"phone":7,"phoneExt":7,"email":16},{"name":33,"role":14,"phone":7,"phoneExt":7,"email":34},"Caroline LALET","c.lalet@bordeaux.unicancer.fr",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100569885",false,"NCT06700057","Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.","Optimisation and Safety of an Innovative Nuclear Medicine Treatment: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.","DOSIPROSTATE","Inclusion Criteria:\n\n1. Patient aged 18 and over.\n2. Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01\u002F11\u002F2023:\n\n   1. Progressive, metastatic, castration-resistant prostate cancer,\n   2. overexpressing prostate specific membrane antigen (PSMA)\n   3. treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone).\n3. Patient able to lie still for 1 hour for image acquisition.\n4. Patient's place of residence \\\u003C 2 hours' drive from the Institut Bergonié.\n5. Patient has not expressed any opposition to the use of his\u002Fher medical data for research purposes.\n\nExclusion Criteria:\n\nNone","MALE","18 Years",{"count":47,"type":48},50,"ESTIMATED","OBSERVATIONAL","Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.",[52,53],"Prostate Cancer","Metastasis",[55],"Radiopharmaceutical drug","2026-01-28",{"date":58,"type":59},"2026-01-30","ACTUAL",{"date":61,"type":59},"2023-11-01",{"date":63,"type":48},"2027-12-31",{"name":5,"class":6},1]